HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
HUTCHMED (China) LimitedNASDAQ: HCM
Other Income / Expenses · Q2 FY2025 · quarter ended Jun 2025
Other income / expenses growth accelerates
Q2 FY2025 other income / expenses of $261.12M rose 823.1% year over year, ahead of the +566.3% change in trailing-twelve-month other income / expenses. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +123.8% a year.
Context
- Other income / expenses amounted to 105.0% of revenue in FY2025, up 90.9 pp from a year earlier.
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +823.1% holds above the trailing-twelve-month pace of +566.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 577.45M USD
- Year-over-year change
- +548.3%
- 4-year CAGR
- +35.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 577.45M | +548.3% |
| FY2024 | 2024-12-31 | 89.07M | +2.1% |
| FY2023 | 2023-12-31 | 87.23M | +69.3% |
| FY2022 | 2022-12-31 | 51.52M | -70.3% |
| FY2021 | 2021-12-31 | 173.19M | — |
Other Income / Expenses vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +566.3% is the highest of 9, against a peer median of -4.8%.
- Other income / expenses amounts to 92.1% of revenue for HCM, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $554.73M USD | +566.3% | +123.8% | 92.1% | |
| LTM Jun 2026 | €260.88M EUR | -46.5% | — | 9.9% | |
| LTM Jun 2026 | $130.03M USD | -55.4% | — | 2.2% | |
| LTM Jun 2026 | $73.27M USD | +112.8% | — | 16.3% | |
| LTM Jul 2026 | $63.96M USD | -15.8% | +28.1% | 2.6% | |
| LTM Mar 2026 | $43.41M USD | -19.7% | +128.0% | 19.3% | |
| LTM Jun 2026 | $34M USD | +6.3% | +33.1% | 29.1% | |
| LTM Jun 2024 | $11.25M USD | — | -72.8% | 173.3% | |
| LTM Sep 2026 | -$1.9M USD | +94.1% | — | 0.1% | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥23.21M CNY | +9.1% | — | 4.2% |
| LTM Jun 2026 | -$427.99M USD | — | — | 10.4% | |
| Peer median (excluding HCM) | — | -4.8% | +30.6% | 10.1% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 356.13M | 426.41M | 838M | 630.2M | 549.96M |
| Cost of Revenue | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M |
| Gross Profit | 97.89M | 115.31M | 453.55M | 281.32M | 212.72M |
| Gross Margin | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| Research & Development | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M |
| Selling, General & Admin | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M |
| Operating Expenses | 426.21M | 523M | 436.23M | 321.93M | 267.45M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| EBITDA | (207.96M) | (401.11M) | 26.58M | (31.36M) | (41.38M) |
| EBITDA Margin | -58.4% | -94.1% | 3.2% | -5.0% | -7.5% |
| Operating Income | (328.32M) | (409.77M) | 18.38M | (43.71M) | (54.73M) |
| Operating Margin | -92.2% | -96.1% | 2.2% | -6.9% | -10.0% |
| Interest Income | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M |
| Interest Expense | 592K | 652K | 759K | 2.87M | 2.87M |
| Other Income / Expenses | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M |
| Income Before Tax | (155.33M) | (360.24M) | 105.6M | 45.36M | 522.72M |
| Pre-Tax Margin | -43.6% | -84.5% | 12.6% | 7.2% | 95.0% |
| Income Tax Expense | 11.92M | (283K) | 4.51M | 7.19M | 63.78M |
| Net Income | (194.65M) | (360.84M) | 100.78M | 37.73M | 458.12M |
| Net Margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (Basic) | (1.25) | (2.15) | 0.60 | 0.22 | 2.65 |
| EPS (Diluted) | (1.25) | (2.15) | 0.60 | 0.22 | 2.60 |
| Weighted Avg Shares | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M |
| Weighted Avg Shares (Diluted) | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.